<DOC>
	<DOCNO>NCT02211443</DOCNO>
	<brief_summary>The purpose study determine whether SCT200 safe tolerant treatment metastatic colorectal cancer</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Recombinant Anti-epidermal Growth Factor Receptor ( EGFR ) Monoclonal Antibody Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>age 18 70 year ; histologically confirm metastatic colorectal cancer ; experienced previous treatment failure include fluoropyrimidine , irinotecan oxaliplatine chemotherapy regiment ; determine wildtype KRAS tumor ; measurable nonmeasurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; expect survival least ≥3 month ; adequate hematological , renal liver function : 1 . Hematological function : white blood cell count &gt; 4.0×109/L ; absolute neutrophil count &gt; 1.5×109/ L ; platelet count &gt; 100×109/L ; hemoglobin level &gt; 90.0 g/L ; 2 . Renal function : serum creatinine level &lt; 1.5×upper limit normal ( ULN ) ; 3 . Liver function : total bilirubin level &lt; 1.5×ULN ; aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) level &lt; 1.5×ULN ; &lt; 5 × ULN patient liver metastasis ; malignancy follow malignancy , require treat curative resection : cervical carcinoma situ , skin basal carcinoma squamous cell carcinoma , bladder epithelial tumor , malignancy requirement surgical therapy disease free survival≥5 year ; serious nonmalignant disease include hypertension , diabetes mellitus , coronary artery disease , mental disorder . pregnant ; lactate ; accept birth control method study ; sign informed consent form approve institutional review board respective medical center . receive EGFR target treatment include EGFR tyrosine kinase inhibitor ( TKI ) , anti EGFR monoclonal antibody ; least 4 week beyond prior anticancer therapy ( include corticosteroid , nitrosourea mitomycin within 6 week study entry ) participate clinical trial , recover significant toxicity prior therapy ; chronic use medication could interfere assessment drugrelated toxicity immunologic activity ( high dose prednisone high dose nonsteroid antiinflammatory medication ) ; recent major surgery ( within 28 day ) ; symptomatically brain metastasis ( exception clinically brain metastasis stable requirement treatment ) ; active infection requirement systemic antibiotic treatment ; serious cardiovascular disease ; evidence active hepatitis B C infection ; human immunodeficiency virus infection ; acute pulmonary disorder ; interstitial pneumonia ; symptomatically chronic obstructive pulmonary disease ( COPD ) risk factor COPD ; eye inflammation infection , risk factor could lead eye disease ; history allergic reaction protein product allergy include antibody product ; pregnant , lactate , accept birth control method include male patient . history alcohol drug addiction , risk may affect patient 's health evaluation mantle state</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Full human anti-EGFR monoclonal antibody ( SCT200 ) ;</keyword>
	<keyword>metastatic colorectal cancer （mCRC） ;</keyword>
	<keyword>Escalating dos ;</keyword>
	<keyword>single dose multiple dos ;</keyword>
	<keyword>safety , tolerability pharmacokinetics .</keyword>
</DOC>